Osteoporosis is major problem in women and geriatric patients where antiresorptive agents are normally recommended. Bisphosphonates (BPs), which have proven efficacy in terms of bone resorption reduction, increase of bone in mineral density, and reduction in fracture risk. Although the oral bioavability of Bisphosphonates is low, their clinical efficacy favors oral administration. Currently marketed oral bisphosphonates preparations suffer from the drawback of discontinuation of therapy due to side effects. This paper provides a comprehensive review of literature on various approaches and technologies attempted to improve the bioavailability and reduce gastric intolerance of oral bisphosphonates. Simultaneously future opportunities for oral delivery of bisphosphonates are also examined. Key words: Bisphosphonates, side effects, poor oral bioavailability, approaches, patented technology, future opportunities.